Fulminant hepatic failure (FHF) is a fatal clinical syndrome that results in excessive inflammation and hepatocyte death. Mitochondrial dysfunction is considered to be a possible mechanism of FHF. Afzelin, a flavonol glycoside found in Houttuynia cordata Thunberg, has anti-inflammatory and antioxidant properties. The present study elucidated the cytoprotective mechanisms of afzelin against D-galactosamine (GalN)/LPS induced FHF, particularly focusing on mitochondrial quality control and dynamics.
Introduction
Fulminant hepatic failure (FHF) is a life-threatening clinical syndrome induced by massive hepatic necrosis. FHF is evoked in a number of clinical situations including bacterial and viral infection, excessive ethanol consumption and other hepatotoxic medications. Administration of LPS with D-galactosamine (GalN) to mice produces a clinically relevant model of hepatitis that resembles both functional and morphological features of human hepatitis (Silverstein, 2004) . Therefore, this model has been widely used to study the pathogenesis of clinical hepatitis and to develop liverprotective reagents. Nevertheless, this animal model has certain limitations as it still does not completely replicate all aspects of FHF in patients. The primary pathophysiological event in GalN/LPS-induced acute liver failure is the release of pro-inflammatory cytokines derived from macrophages. Emerging evidence now indicates that mitochondrial dysfunction is a possible mechanism of GalN/LPS-induced FHF, which causes disruption of ATP synthesis, ROS overproduction, and the release of pro-apoptotic proteins and other factors, resulting in cell death (Lee et al., 2007) . While a plethora of studies have investigated the characteristics of FHF, the exact mechanisms are still unclear.
Mitochondrial quality control and dynamics are essential for regulating mitochondrial homeostasis. Mitochondrial biogenesis and mitophagy play central roles in mitochondrial quality control and must be well coordinated to properly regulate cellular adaptation in response to mitochondrial damage. A recent study suggested that hepatocyte survival and function in sepsis depend on mitochondrial homeostasis, manifest as mitophagy and biogenesis (Carchman et al., 2013) . Astragaloside was found to inhibit ROS overproduction, which resulted in an enhancement of mitochondrial biogenesis and mitophagy, thus preventing mitochondrial dysfunction in angiotensin II-stimulated rat vascular smooth muscle cells (Lu et al., 2015) . Mitochondrial dynamics comprising fission and fusion processes regulate mitochondrial morphology and distribution. These processes are integrated with the control of mitochondrial biogenesis and mitophagy determining mitochondrial morphology. Excessive mitochondrial fragmentation with increased fission or impaired fusion is a hallmark of many neurodegenerative diseases and contributes to their pathophysiology (Haun et al., 2013) . Kim et al. (2013) demonstrated that hepatitis B virus induces mitochondrial fission, which contributes to mitochondrial dysfunction and cell injury. Furthermore, aberrations in the mitochondrial fusion and fission balance was also shown to contribute to mitochondrial biogenesis (Song et al., 2015) . Mitochondrial biogenesis and mitophagy are tightly regulated by several molecules including AMPK, sirtuin 1 (SIRT1) and p53 (Scarpulla et al., 2012; Boland et al., 2013) . The orphan nuclear receptor Rev-Erb-α controls several metabolism and cell survival genes including SIRT1 and PPAR-γ coactivator 1α (PGC1α). (Wu et al., 2009; Vieira et al., 2013) . In a recent study, it was demonstrated that Rev-Erb-α controls cellular homeostasis by regulating mitochondrial biogenesis and mitophagy (Woldt et al., 2013) .
Afzelin (kaempferol 3-O-rhamnoside) is a flavonol glycoside found in Houttuynia cordata Thunberg and is widely used in the preparation of antibacterial and antipyretic agents, detoxicants and for the treatment of inflammation (Satthakarn et al., 2015) . Recently, H. cordata extract protected the liver injury caused by a high-fat diet and acetaminophen in rodent models (Chen et al., 2014; Kang and Koppula, 2015) . Afzelin has potent anti-inflammatory, anticancer and anti-oxidative effects (Rho et al., 2011; Choe et al., 2012) . Afzelin has been shown to attenuate the oxidative stress, disruption of the mitochondrial membrane potential and mitochondrial permeability induced by UV in human skin (Shin et al., 2013) . Kaempferol was shown to prevent inactivation of mitochondrial complex IV and ROS production in antimycin A-treated osteoblast-like MC3T3-E1 cells (Choi, 2011) . However, the in vivo hepatoprotective effects of afzelin remain unclear. Therefore, we investigated the hepatoprotective mechanisms of afzelin in FHF, particularly concentrating on the regulation of mitochondrial quality control and dynamics.
Methods

Group sizes, randomization and blinding
Ten mice per group were chosen. Mice were selected from the pool eligible for inclusion in the study and were randomly divided into four groups. Randomization was performed for These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 ( a,b Alexander et al., 2015a,b) .
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the day of starvation, and afzelin treatment was based on body weight. All experiments were performed in a blinded manner.
Animals
Male ICR mice (8-9 weeks of age) were purchased from Daehan Biolink Inc. (Eumseong, Korea) and placed in cages (n = 5 mice per cage). All cages were kept at 25 AE 1°C and 55 AE 5% air humidity under a 12 h light-dark cycle, with ad libitum feeding. Mice were acclimatized to the cages for 7 days, and they were habituated to handling before the experiments. Mice were observed carefully for symptoms or wounds that would results in their premature removal from the experiment. Animals received care in compliance with the Principles of Laboratory Animal Care formulated by the National Institutes of Health (NIH publication no. 86-23, revised 1985) and all experiments were approved by the Animal Care Committee of Sungkyunkwan University School of Pharmacy (SKUIACUC-20150010) on the basis of the 3Rs (replacement, refinement and reduction). Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Validity of animal model or model selection
GalN/LPS-induced liver damage is a widely used model that represents clinical hepatic failure. In this GalN/LPS model, macrophages produce pro-inflammatory cytokines. There is accumulating evidence demonstrating that regulation of inappropriate inflammation is a novel strategy for treating FHF.
Experimental design
Mice, other than the controls, were injected, i. GalN/LPS treatment. The doses and timing of the afzelin treatment were selected according to results from a previous study and our preliminary study (Cho et al., 2015; Furtado et al., 2015) . Animals were divided into eight groups (n = 10 mice per group): (i) vehicle-treated control (control), (ii) afzelin at a dose of 200 mg·kg ) and xylazine (7 mg·kg À1 ), and they were killed 5 h after the GalN/LPS injection. Blood was collected from the inferior vena cava, centrifuged (1000 × g, 10 min, 4°C) to yield a serum, and stored at À75°C for later analysis. Liver tissue was also isolated 5 h after GalN/LPS injection and stored at À75°C for later analysis.
Plant material
The dried aerial parts of Houtuynia cordata Thunberg (Saururaceae) were purchased from a Herbal Market (Seoul, Korea) and identified by Professor Je-Hyun Lee (Dongguk University, Gyoungju, Korea). The voucher specimen (SNUPH2013-02) has been deposited in the Herbarium of the Medicinal Plant Garden (College of Pharmacy, Seoul National University, Seoul, Korea).
Extraction and isolation
The dried aerial parts of H. cordata were crushed and then extracted with methanol (3 × 30 L; Sigma-Aldrich) by sonication (90 min, 3 times) at room temperature. After removal of the solvent by vacuum, the methanol extract was subjected to Diaion HP-20 chromatography and eluted with 90% methanol to remove chlorophyll. After this process, the collected fraction was suspended in H 2 O, and then divided into four fraction layers with n-hexane, chloroform, ethyl acetate and n-butanol. The flavonoid-enriched ethyl acetate fraction was subjected to silica gel column chromatography (30 × 7.5 cm) and eluted with chloroform/methanol (20:1 → 0:1, step-gradient system), to yield fourteen fractions (EA01-14). Afzelin was isolated from fraction EA09 by preparative reverse phase-HPLC (Phenomenex Luna C18 (2) Hz, H-6″). The 13 C NMR spectrum (CD 3 OD, 100 MHz) showed the presence of X resonances at δ 179.6 (C-4), 165.8 (C-7), 163.2 (C-4´), 161.6 (C-5), 159.3 (C-9), 158.6 (C-2), 136.2 (C-3), 131.9 (C-2´), 122.6 (C-6), 116.8 (C-1´), 116.5 (C-3´), 116.1 (C-5´), 105.9 (C-10), 103.5 (C-1´´), 99.8 (C-6), 94.7 (C-8), 73.2 (C-4´´), 72.1 (C-2´´), 72.0 (C-3´´), 71.9 (C-5´´), 17.6 (C-6´´). The compound was identified as afzelin by comparison of the spectral data with those reported previously (Lee et al., 2014) .
Survival rate and serum alanine aminotransferase activity
The survival rate of mice was monitored for 24 h after injection of GalN/LPS. Mice were observed for morbidity each hour after the injection of GalN/LPS, and any moribund mice were immediately killed with an overdose of ketamine and xylazine. Serum activity was measured by standard spectrophotometry with a ChemiLab alanine aminotransferase (ALT) assay kit (IVDLab Co., Ltd., Uiwang, Korea).
Histological analysis
Left lobes of liver tissues were isolated, fixed immediately with 10% neutral buffered formalin (Sigma-Aldrich), embedded in paraffin, cut into 5 μm sections and stained with haematoxylin and eosin for blinded histological assessment. Histological changes were evaluated in randomly chosen histological fields at 400× magnification using an optical microscope (Olympus Optical Co., Tokyo, Japan).
Serum TNF-α and IL-6 levels
Serum TNF-α and IL-6 levels were measured 5 h after injection of GalN/LPS with a commercial mouse enzyme-linked immunosorbent assay kit (eBioscience, San Diego, CA, USA) according to the manufacturerˈs instructions.
ATP analysis
Frozen liver tissue was homogenized in 1.5 M perchloric acid. Following centrifugation, supernatants were neutralized by 0.5 M dithiothreitol and were kept on ice until injection into a HPLC system to determine the hepatic ATP level. A Waters 2690 HPLC system (Agilent Technologies, Santa Clara, CA, USA) was used to determine the ATP content in samples. ATP was separated on a Phenomenex Luna C18 column equipped with a UV detector (Waters 2487; Agilent Technologies). The column was eluted at a flow rate of 1 mL·min À1 with HPLC buffer A (0.1 M ammonium phosphate monobasic) and a linear gradient of buffer B (acetonitrile) reaching 5% in 15 min. The mobile phase then reached 95% of buffer B over 35 min in a linear gradient. The absorbance was measured at 254 nm wavelength, and the ATP level was calculated from computer-integrated areas in the chromatogram peaks in relation to the areas obtained for the standard solutions.
Electron microscopy
Liver tissue was fixed in 0.1 M sodium phosphate buffer containing 2.5% glutaraldehyde and 4% paraformaldehyde (pH 7.2) and rinsed with 0.1 M Na cacodylate buffer (pH 7.4). Subsequently, fixed liver tissue was postfixed in 2% osmium tetroxide and washed repeatedly. Samples were dehydrated through a series of ethanol and propylene oxide and then embedded in epoxy resin (Taab 812 Resin; Marivac Industries, Montreal, QC, Canada 
Mitochondrial DNA analysis
Mitochondrial DNA (mtDNA) was extracted from liver tissue using a DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA). To amplify the mtDNA, real-time quantitative RT-PCR (qRT-PCR) was used with a thermocycler (Lightcycler® Nano, Roche Applied Science, Mannheim, Germany) and the SYBR Green detection system (Roche Applied Science). The primers used were as follows; 5 0 -ACGCTTCCGTTACGATCAAC-3 0 (sense) and 5 0 -ACTCCCGCTGTAAAAATTGG-3 0 (antisense) for mitochondrial NADH dehydrogenase 1 (ND1) and 5 0 -AGCCATGTACGTAGCCATCC-3 0 (sense) and 5 0 -GCTGTG GTGGTGAAGCTGTA-3 0 (antisense) for β-actin. qRT-PCR was performed with an initial denaturation at 94°C for 5 min and a final extension at 72°C for 7 min. The cycling conditions were as follows: 45 cycles of 30 s at 94°C, 30 s at 52°C and 30 s at 72°C for ND1, and 45 cycles of 30 s at 94°C, 30 s at 55°C and 30 s at 72°C for β-actin. The mtDNA copy number was quantified relative to both β-actin and the average of all δ cycle threshold-values in each sample using the cycle threshold method. All analyses were conducted in duplicate to ensure amplification integrity.
Isolation of liver mitochondria
Liver tissue and subcellular fractions were obtained as previously described (Johnson and Lardy, 1967) . The tissue was homogenized in a medium containing 250 mM sucrose, 10 mM Tris-HCl, and 1 mM EDTA (pH 7.2 at 4°C). The homogenate was centrifuged at 600 x g for 10 min, and the supernatant was collected in a new e-tube. The supernatant was subsequently centrifuged for 5 min at 15 000 x g to obtain a mitochondrial pellet. The mitochondrial pellet was washed with a medium without EDTA and then centrifuged for 5 min at 15 000 x g, producing the final pellet.
Mitochondrial glutamate dehydrogenase activity
Mitochondria were homogenized in Triton X-100 (0.05% v·v À1 ) containing 50 mM KH 2 PO 4 and 1 mM EDTA (pH 7.5) at 4°C. The suspension was used for a glutamate dehydrogenase (GDH) activity assay, as described previously (Ellis and Goldberg, 1972) .
Hepatic mitochondrial lipid peroxidation
Malondialdehyde (MDA) was measured as the end product of lipid peroxidation. Thiobarbituric acid-reactive substances were determined by measuring the absorbance at 532 nm wavelength, and 1,1,3,3-tetraethoxypropane (Sigma-Aldrich) was used as the standard.
Mitochondrial swelling
The mitochondrial swelling, an indicator of mitochondrial permeability transition (MPT), was measured by the change in the absorbance of a mitochondrial suspension at 520 nm (Elimadi et al., 2001) . Briefly, liver mitochondria were isolated from each experimental group, and added to 4 mL of phosphate buffer containing 250 mM sucrose, 5 mM KH 2 PO 4 and 1 μM rotenone (pH 7.2) at 25°C. This suspension was put into the sample and reference cuvettes. Subsequently, 6 mM succinate was only added to the sample cuvette.
Western blot immunoassay
Liver tissue (80 mg) was homogenized in PRO-PREP (iNtRON Biotechnology Inc., Seongnam, Korea) containing a phosphatase inhibitor. Tissue homogenates were centrifuged at 12 000 × g for 15 min and the supernatant was collected.
The total protein concentrations of liver lysates and mitochondrial pellets were determined with a BCA protein assay kit (Pierce Biotechnology Inc., Rockford, IL, USA). The protein samples were then loaded onto 7.5-15% polyacrylamide gels and separated by SDS/PAGE before being transferred to PVDF membranes (Millipore, Billerica, MA, USA) on a semidry trans-blot cell (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membranes were blocked and the blots were incubated overnight at 4°C with primary antibodies. After being washed with Tween 20 in 1X Tris-buffered saline, the membranes were incubated with appropriate secondary antibodies for 1 h at room temperature and detected with an ECL detection system (iNtRON Biotechnology Inc.). The intensity of the immunoreactive bands was determined with TotalLab TL 120 software (Nonlinear Dynamics Ltd., Newcastle, UK). The primary antibodies used were as follows: mitofusin 2 (Mfn2), nuclear respiratory factor 1 (Nrf1), sequestosome1/p62 (p62), PGC1α, SIRT1, mitochondrial transcription factor A (TFAM) (Abcam, Cambridge, MA, USA), phosphorylated AMPK (phospho-AMPK), Rev-Erb-α (Cell Signalling Technology, Beverly, MA, USA), microtubule-associated protein 1 light chain 3 (LC3) (Novus Biologicals, Littleton, CO, USA), dynamin-related protein 1 (Drp1), GAPDH, Parkin, PTEN-induced putative kinase 1 (PINK1) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and β-actin (Sigma-Aldrich). The levels of protein expression were normalized relative to the corresponding β-actin or GAPDH band intensity.
Statistical comparison
The data obtained were analysed using GraphPad software (GraphPad Software, Inc., La Jolla, CA). The result of survival rate was presented with Kaplan-Meier curves and analysed by the log-rank test. All other results are presented as mean AE SEM and were analysed by one-way ANOVA; Bonferroniˈs test was used for multiple comparisons. Statistical differences between groups were considered significant at the P < 0.05 level. The data and statistical analysis comply with the recommendations for experimental design and analysis in pharmacology (Curtis et al., 2015) .
Results
Afzelin alleviates hepatic injury in GalN/LPS-treated mice
To determine the effect of afzelin on GalN/LPS-induced mortality and hepatic damage, we measured survival for 24 h after GalN/LPS injection. At 6 h after GalN/LPS injection, mice began to die and mortality reached 80% at 24 h. Afzelin treatment (50, 100 and 200 mg·kg À1 ) dose-dependently improved the survival rate (Figure 1 ). Serum ALT activity, a traditional serum marker of necrotic cell death in hepatocytes, was 31.4 AE 6.5 U·L À1 in the control group (Table 1) . At 5 h after GalN/LPS treatment, serum ALT activity was significantly increased by 13.7-fold compared to that in the control group, and this increase was attenuated by afzelin administration at doses of 50, 100 and 200 mg·kg À1 . The serum levels of TNF-α and IL-6 were 37.6 AE 3.3 and 60.9 AE 6.5 pg·mL À1 , respectively, in the control group. Serum TNF-α and IL-6 levels were significantly increased by 5.0-and 17.5-fold, respectively, compared with those in the control group at 5 h after GalN/LPS treatment, and these increases were attenuated dose-dependently by afzelin at doses of 50, 100 and 200 mg·kg À1 (Table 1) . On the basis of these results, 200 mg·kg À1 afzelin was chosen as the optimal dose for further studies. Histological observations of the liver samples strongly supported these effects of GalN/LPS on serum ALT activity and levels of TNF-α and IL-6 as well as the protective effect of afzelin. The histology in the control group showed normal liver conditions. However, 5 h after GalN/LPS treatment, the liver had extensive infiltration of immune cells and necrosis. These pathologies were ameliorated by afzelin treatment (Figure 2A) . Afzelin alone at a 
Afzelin reduces mitochondrial dysfunction in GalN/LPS-treated mice
To investigate the effect of afzelin on mitochondrial dysfunction, we measured mitochondrial GDH activity and hepatic ATP levels (markers of mitochondrial dysfunction). Mitochondrial GDH activity was 4.3 AE 0.1 U·mg protein À1 and the hepatic ATP level was 2.4 AE 0.2 μmol·g liver À1 in the control group. At 5 h after GalN/LPS treatment, mitochondrial GDH activity and the hepatic ATP level were markedly decreased to approximately 68% and 52% of those in the control group respectively. These changes were attenuated by afzelin ( Figure 3A , B).
Afzelin decreases mitochondrial lipid peroxidation and swelling in GalN/LPS-treated mice
The mitochondrial MDA level in the control group was 1.1 AE 0.0 nmol·mg protein
À1
. At 5 h after GalN/LPS treatment, the mitochondrial MDA level was increased significantly by approximately 1.9-fold compared with that in the control group. This increase was attenuated by afzelin ( Figure 3C ). The mitochondria isolated from all groups swelled after being energized with succinate. The rate of mitochondrial swelling at 5 h after GalN/LPS treatment was significantly higher than that in the control group. This rapid increase in mitochondrial volume was decreased by afzelin ( Figure 3D ). Afzelin alone did not affect the mitochondrial MDA level or the rate of mitochondrial swelling.
Afzelin inhibits mitophagy in GalN/LPS-treated mice
The expressions of mitochondrial PINK1 and parkin protein in the GalN/LPS-treated group were significantly increased by 1.7-fold and 4.0-fold, respectively, compared with those in the control group and these increases were attenuated by afzelin ( Figure 4A, B) . In addition, the hepatic ratio of LC3-II/LC3-I, an autophagosome marker, was significantly increased by 2.1-fold compared with that in the control group at 5 h after GalN/LPS treatment. This increase was attenuated by afzelin ( Figure 4C ). The expression of hepatic p62 protein, a selective substrate of autophagy, at 5 h after GalN/LPS treatment was markedly decreased to approximately 32% of that in the control group. The decrease in p62 protein expression was attenuated by afzelin ( Figure 4D ). To confirm our western blot results, we evaluated mitophagy using TEM. Liver tissues examined after afzelin treatment exhibited fewer autophagic vacuoles ingesting mitochondria compared to livers from the GalN/LPS group ( Figure 2B ). Moreover, we used the autophagy inhibitor, CQ, to determine the role of mitophagy in the GalN/LPS-treated group. In the present study, CQ further increased the LC3-II/LC3-I ratio and blocked p62 degradation ( Figure 5A, B) . Furthermore, CQ attenuated the increased serum ALT activity, decreased mitochondrial GDH activity, and increased rate of mitochondrial swelling induced by GalN/LPS treatment ( Figure 5C -E).
Afzelin increases mitochondrial biogenesis in GalN/LPS-treated mice
At 5 h after GalN/LPS injection, the mtDNA copy number was significantly decreased to 26% of that in the control group; this effect was attenuated by afzelin ( Figure 6A) . The protein expression level of hepatic PGC1α, Nrf1 and TFAM in the GalN/LPS-treated group was significantly decreased to 46%, 68% and 45%, respectively, compared with that in the control group; again these effects were attenuated by afzelin ( Figure 6B-D) .
Afzelin inhibits mitochondrial dynamics in GalN/LPS-treated mice
Mitochondrial dynamics consist of fusion and fission. Mitochondrial fission is mediated by the hepatic protein Drp1, while fusion is regulated by Mfn2. The Drp1 level was significantly increased by 1.5-fold in the GalN/LPS-treated group compared with that in the control group. This increase was attenuated by afzelin ( Figure 6E ). In contrast, the Mfn2 level was markedly decreased in the GalN/LPS-treated group, to 43% of that in the control group; again this effect was attenuated by afzelin ( Figure 6F ). The role of mitochondrial dynamics in protection against liver injury was further confirmed by the mitochondrial fission inhibitor, mdivi-1. Mdivi-1 decreased the level of Drp1 protein expression in GalN/LPS-treated mice. Furthermore, mdivi-1 attenuated the increased serum ALT activity and decreased mitochondrial GDH activity in addition to attenuating the increased rate of mitochondrial swelling induced by GalN/LPS treatment ( Figure 7A-D) .
Afzelin increases Rev-Erb-α, phospho-AMPK and SIRT1 protein expression in GalN/LPS-treated mice
To investigate the molecular mechanism by which GalN/LPS and afzelin affect mitophagy and mitochondrial biogenesis, we assessed the protein expression of Rev-Erb-α, phospho-AMPK and SIRT1. The level of Rev-Erb-α protein expression in the GalN/LPS group was decreased markedly to 53% of that in the control group ( Figure 8A ). The levels of phospho-AMPK and SIRT1 proteins, the downstream signalling molecules of Rev-Erb-α, in the GalN/LPS-treated mice were decreased significantly to 78% and 52% of those in the control group respectively. Afzelin treatment restored the reduced Rev-Erb-α, phospho-AMPK and SIRT1 protein levels ( Figure 8B, C) . 
Discussion
Considerable efforts have been made to determine the mechanism underlying fulminant hepatitis as the prognosis of this condition remains quite poor; there are no effective therapies other than liver transplantation. Flavonoids are a large group of plant-derived compounds, and it is well-established that certain flavonoids exhibit anti-inflammatory properties. Previous studies have demonstrated that pretreatment with flavonoids effectively decreased mortality in in vivo GalN/LPS models (Wan et al., 2008; Lee et al., 2011; Gao et al., 2016) . Although clinicians are involved in the treatment rather than prevention, there may be certain high-risk individuals who would benefit from a treatment that would protect them against the effects of FHF. Prevention of FHF could be meaningful in patients with chronic liver disorders or even cirrhosis associated with a high risk of FHF (Singh et al., 2016) . Our recent in vitro study demonstrated that afzelin has potent hepatoprotective, anti-inflammatory and antioxidant activities in both GalN-and t-butyl hydroperoxide-treated primary hepatocytes (data not shown). In the present study we clearly demonstrated that afzelin protects mice from GalN/LPSinduced lethality in a dose-dependent manner. Interestingly, at a dose of 200 mg·kg À1 afzelin, the survival rate was 100% at 24 h after GalN/LPS injection. Furthermore, the hepatic damage observed following GalN/LPS injection, as indicated by elevated serum ALT activity, increased TNF-α and IL-6 levels, and histological features, was attenuated by afzelin
Figure 5
Effect of mitophagy in GalN/LPS-treated mice. Mice received an i.p. injection of vehicle or CQ (60 mg·kg À1 ) 1 h before GalN (800 mg·kg À1 )/LPS (40 μgkg À1 ) treatment. Western blot analysis was performed to measure the protein levels of (A) hepatic ratio of LC3-II/LC3-I and (B) p62 in the CQ-treated group. (C) Serum ALT, (D) mitochondrial GDH activity and (E) the rate of mitochondrial swelling were measured in the CQ-treated group. The expression of each protein was adjusted to β-actin as the loading control. The ratio of the LC3-II and LC3-I bands was evaluated by densitometric analysis. All values are expressed as mean AE SEM of 10 mice per group. * Significantly different (P < 0.05) from the control group. + Significantly different (P < 0.05) from the GalN/LPS group. treatment. Our results suggest that afzelin may have potential as a clinical treatment for liver disease.
Mitochondrial dysfunction plays a critical role in GalN/LPS-induced liver injury. Mitochondrial GDH, a mitochondrial matrix enzyme, is a hallmark of mitochondrial damage. In the liver ischaemia/reperfusion model, mitochondrial injury was indicated by decreased mitochondrial GDH activity . In the present study, we showed that the GalN/LPS treatment decreased mitochondrial GDH activity. The mitochondria isolated from mice treated with afzelin showed higher GDH activity than that in the control group, which suggests that afzelin improves mitochondrial dysfunction after GalN/LPS treatment. Indeed, the hepatic ATP level, a marker of mitochondrial function, was higher in afzelin-treated mice than in the GalN/LPS group. Mitochondria are the main source of ROS and also a target organelle for oxidative stress. Oxidative stress promotes mitochondrial depolarization by triggering permeability transition pore opening and large-amplitude mitochondrial swelling. In GalN/LPS-treated mice, the lipid peroxidation level and mitochondrial swelling rate were significantly increased compared to the controls, and afzelin attenuated these increases. Guo et al. (2015) showed that kaempferol reduced anoxia/reoxygenation-induced ROS production and the extent of the opening of MPT pore in primary cardiomyocytes. Collectively, our results indicate that afzelin inhibits the oxidative mitochondrial damage induced by GalN/LPS injection, and is considered to act as a protective agent. Mitochondrial homeostasis and the maintenance of their function are crucial to cell physiology. Both mitophagy and mitochondrial biogenesis coordinate the mitochondrial quantity and quality, thereby regulating mitochondrial function and preserving homeostasis. An imbalanced response to either process impairs the biological function and results in cell death (Degli Esposti et al., 2012) . Mitophagy is essential for the selective elimination of abnormal mitochondria. Mitophagy can prevent apoptotic and necroptic cell death by degrading damaged mitochondria, which might trigger cell death (Kubli and Gustafsson, 2012) . In most mammalian cells, PINK1 and parkin play a major role in mediating the canonical mitophagy pathway. The translocation of parkin is induced by the accumulation of PINK1 on the outer membrane of mitochondria (Kim et al., 2008) . After parkin is recruited to the outer membrane of mitochondria, the autophagic substrate protein p62 binds and tethers the mitochondria to the LC3-positive phagophore, leading to autophagosome formation and finally abnormal mitochondria are degraded by fusion with lysosome (Kubli and Gustafsson, 2012) . Despite the protective effects of mitophagy, there is increasing evidence indicating that excessive mitophagy impairs cells by inducing the disposal of too many mitochondria (Pi et al., 2013) . Overactive mitophagy can lead to programmed cell death in a chronic obstructive pulmonary disease model (Ito et al., 2015) . PINK1 knockout mice are less susceptible to the loss of mitochondrial membrane integrity by inhibition of mitophagy in cigarette smoke-induced lung injury (Mizumura et al., 2014) . In the present study, the protein expression of mitochondrial PINK1 and parkin was markedly augmented in GalN/LPS-treated mice. Moreover, the hepatic ratio of LC3-II/LC3-I was increased and the protein expression of p62 was decreased in GalN/LPS-treated mice, indicating that GalN/LPS increased mitophagy. These changes were attenuated by afzelin. CQ, an inhibitor of lysosomal acidification, significantly increased p62 protein accumulation and reduced liver injury, as demonstrated by a decrease in serum ALT activity. Accordingly, TEM images showed that the number of autolysosomes including partially degraded mitochondrial organelles in the liver of mice was comparably greater in afzelin-treated GalN/LPS animals than in control animals. These results suggest that afzelin protects against GalN/LPSinduced FHF by suppressing excessive mitophagy. Mitochondrial biogenesis is a carefully regulated process that promotes mitochondrial capacity through the replication of mtDNA and mitochondrial growth, which alleviates mitochondrial dysfunction following injury in several pathophysiological models (Lee and Wei, 2005) . Massive mitophagy induces a lack of biogenesis and results in the exhaustion of the bioenergetic reserve in the remaining mitochondria and leads to cell death (Kubli and Gustafsson, 2012) . PGC1α is intimately involved in the regulation of mitochondrial biogenesis, due to its ability to induce nuclear translocation and co-activate the transcription of numerous downstream mediators of mitochondrial biogenesis (Austin and St-Pierre, 2012) . One downstream mediator, Nrf1, regulates nuclear gene transcription by involving mitochondrial respiratory chain proteins including complexes I, II, III, IV and V, cytochrome c and transcriptional factors, including TFAM, which regulate and maintain mtDNA replication and transcription (Kelly and Scarpulla, 2004) . Furthermore, TNF treatment decreased PGC1α and Nrf1 mRNA expression in 3T3-L1 adipocytes (Hahn et al., 2014) . Rutin, a flavonoid glycoside composed of quercetin, induces mitochondrial biogenesis as indicated by an increase in mtDNA content and mitochondrial size (Seo et al., 2015) . In our study, GalN/LPS treatment decreased the mtDNA copy number as well as the levels of protein expression of PGC1α, Nrf1 and TFAM. Afzelin attenuated these decreases, suggesting that it activates mitochondrial biogenesis.
Mitochondrial dynamics cause changes in mitochondrial morphology, which are essential to retain mitochondrial integrity by maintaining DNA or protein quality control. Mitochondrial fission and fusion are the major processes that maintain mitochondrial morphology. Although a fusion and fission imbalance results in cellular dysfunction and cell death, the mechanism involved is not fully understood. Fission, the division or fragmentation of mitochondria by fission proteins, is important for cell proliferation and death (Das et al., 2014) . Suen et al. (2008) showed that excessive mitochondrial fission was required for the intrinsic apoptosis pathway. The primary executioner of mitochondrial fission is Drp1, which polymerizes into a chain. Inhibition of excessive Drp1 activation was shown to reduce excessive mitochondrial fission and improve mitochondrial and cardiac dysfunction in an ischaemia and reperfusion model (Disatnik et al., 2013) . In the present study, afzelin suppressed GalN/LPS-induced Drp1 up-regulation. Mdivi-1, a mitochondrial fission inhibitor, prevents mitochondrial fragmentation in vivo (Marsboom et al., 2012) . In our study, mdivi-1 treatment attenuated the increased serum ALT activity and decreased GDH activity and reduced the rate of mitochondrial swelling in GalN/LPS-treated mice. To confirm that the protective effect of afzelin against hepatocellular damage is really mediated through Drp1, we performed Drp1 gene silencing by siRNA. Drp1 siRNA did not affect the inhibition of ALT and GDH release by afzelin in LPS-stimulated HepG2 cells. These data indicate that Drp1 is necessary for the protective effects of afzelin against GalN/LPS-induced hepatic injury. Fusion allows intact mitochondria to merge with dysfunctional mitochondria, thereby recovering the damaged mtDNA and restoring mitochondrial integrity (Das et al., 2014) . Mfn2 is embedded in mitochondrial outer membrane and mediates mitochondrial fusion by the tethering of two adjacent mitochondria (Liesa et al., 2009) . Cells with fully depleted Mfn2 genes lack mitochondrial fusion and exhibit marked cellular defects in embryos (Chen et al., 2005) . In our study, afzelin suppressed the GalN/LPS-induced down-regulation of Mfn2. Overall, these results indicate that afzelin reduces mitochondrial fission and increases mitochondrial fusion, which regulate mitochondrial dynamics. Several signalling molecules, such as AMPK, SIRT1 and p53, regulate mitochondrial biogenesis and mitophagy. (Boland et al., 2013; Scarpulla et al., 2012) . Rev-Erb-α, a nuclear receptor, is expressed in the liver and modulates lipid and glucose metabolism as well as the inflammatory response of macrophages by interacting with a number of genes such as SIRT1 and PGC1α (Vieira et al., 2013; Wu et al., 2009 ). Rev-Erb-α also regulates cellular homeostasis by preserving mitochondrial function, and this assists an organism to endure oxidative and environmental stress (Sengupta et al., 2016) . Rev-Erb-α increases PGC1α expression and function by activating AMPK/SIRT1-signalling. Indeed, Rev-Erb-α regulates oxidative capacity in skeletal muscle by regulating mitochondrial biogenesis and autophagy (Woldt et al., 2013) . However, it is still unclear whether Rev-Erb-α regulates mitophagy and mitochondrial biogenesis in an in vivo liver injury model. In the present study, intriguingly, afzelin increased hepatic Rev-Erb-α as well as phospho-AMPK and SIRT1 protein expression in the GalN/LPS treated group. Our results indicate that Rev-Erb-α is involved in the regulation of mitophagy and mitochondrial biogenesis by afzelin. It is also plausible that Rev-Erb-α directly regulates mitochondrial quality control, although this remains to be studied.
In conclusion, these results suggest that afzelin attenuates GalN/LPS-induced mitochondrial damage through the enhancement of mitochondrial biogenesis and suppression of excessive mitophagy. Enhancement of mitochondrial quality control through pharmacological regulation of mitochondrial function and dynamics is emerging as a strategy for preventing mitochondrial disorders. Therefore, afzelin may provide a new pharmacological intervention option for FHF.
